Cargando…
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
The ICARUS trial is a phase II, open label, multicenter, single arm study conducted to investigate the efficacy, safety, and tolerability of a rechallenge treatment with the first-generation tyrosine kinase inhibitor (TKI) gefitinib in advanced non-small-cell lung cancer (NSCLC) patients carrying ac...
Autores principales: | Esposito Abate, Riziero, Pasquale, Raffaella, Sacco, Alessandra, Piccirillo, Maria Carmela, Morabito, Alessandro, Bidoli, Paolo, Finocchiaro, Giovanna, Chiari, Rita, Foltran, Luisa, Buosi, Roberta, Tiseo, Marcello, Giannetta, Laura, Battiloro, Ciro, Fasola, Gianpiero, Romano, Gianpiero, Ciuffreda, Libero, Frassoldati, Antonio, de Marinis, Filippo, Cappuzzo, Federico, Normanno, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826724/ https://www.ncbi.nlm.nih.gov/pubmed/31557965 http://dx.doi.org/10.3390/cancers11101431 |
Ejemplares similares
-
Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011) -
Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013) -
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
por: Roma, Cristin, et al.
Publicado: (2022) -
Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020) -
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)